Last reviewed · How we verify
Placebo/Vehicle cream
Placebo/vehicle cream contains no active pharmaceutical ingredient and serves as a control formulation in clinical trials.
At a glance
| Generic name | Placebo/Vehicle cream |
|---|---|
| Sponsor | Actavis Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo or vehicle cream is an inert topical formulation used as a comparator in clinical trials to establish the efficacy of an active drug. It typically contains the same base ingredients (emollients, preservatives, etc.) as the active formulation but lacks the therapeutic agent, allowing researchers to distinguish true drug effects from vehicle effects or natural disease progression.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial) (PHASE2)
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (PHASE3)
- Topical Ketotifen 0.25% for Secondary Vestibulodynia (PHASE2)
- Topical Anti-Androgens in Pilonidal Sinus Disease (PHASE2)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) (PHASE3)
- Topical Sirolimus in Cutaneous Lymphatic Malformations (PHASE2)
- Basal Cell Carcinoma Chemoprevention Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo/Vehicle cream CI brief — competitive landscape report
- Placebo/Vehicle cream updates RSS · CI watch RSS
- Actavis Inc. portfolio CI